Circulating microRNA expression is associated with genetic subtype and survival of multiple myeloma

Circulating microRNAs (miRNAs) have shown potential as non-invasive prognostic biomarkers in cancer. Here, we investigated whether miRNAs present in the plasma of multiple myeloma (MM) patients have prognostic utility. We evaluated global miRNA expression profiles in the plasma of 12 multiple myeloma patients and 8 healthy controls using TaqMan Low-Density Arrays. Six miRNAs (miR-148a, miR-181a, miR-20a, miR-221, miR-625, and miR-99b) that were significantly upregulated in MM were selected and further quantified independently by quantitative reverse transcription PCR in plasma from 28 MM patients and 12 healthy controls. Moreover, within the patient group, the expression levels of miR-99b and miR-221 were associated with chromosomal abnormalities t(4; 14) and del(13q), respectively. High levels of miR-20a and miR-148a were related to shorter relapse-free survival. In summary, we have identified aberrant expression of particular circulating miRNAs that are associated with the genetic subtype and survival of MM. These plasma miRNAs have potential as clinical biomarkers in MM.

[1]  C. Burge,et al.  Conserved Seed Pairing, Often Flanked by Adenosines, Indicates that Thousands of Human Genes are MicroRNA Targets , 2005, Cell.

[2]  Hsuan-Cheng Huang,et al.  Integrative network analysis reveals active microRNAs and their functions in gastric cancer , 2011, BMC Systems Biology.

[3]  Eun Kyung Kim,et al.  Aberrant expression of let-7a miRNA in the blood of non-small cell lung cancer patients. , 2011, Molecular medicine reports.

[4]  Xin Zhou,et al.  Altered expression of miR-152 and miR-148a in ovarian cancer is related to cell proliferation. , 2011, Oncology reports.

[5]  J. Chi,et al.  MicroRNA expression in multiple myeloma is associated with genetic subtype, isotype and survival , 2011, Biology Direct.

[6]  Vivek Jayaswal,et al.  Expression profiling of cytogenetically normal acute myeloid leukemia identifies MicroRNAs that target genes involved in monocytic differentiation , 2011, American journal of hematology.

[7]  Jianyong Li,et al.  miR-17-92 cluster microRNAs confers tumorigenicity in multiple myeloma. , 2011, Cancer letters.

[8]  H. Tagawa,et al.  Synergistic action of the microRNA‐17 polycistron and Myc in aggressive cancer development , 2007, Cancer science.

[9]  S. Grimmond,et al.  The miR-17-5p microRNA is a key regulator of the G1/S phase cell cycle transition , 2008, Genome Biology.

[10]  Xianghuo He,et al.  MicroRNA-148a Suppresses Tumor Cell Invasion and Metastasis by Downregulating ROCK1 in Gastric Cancer , 2011, Clinical Cancer Research.

[11]  J. Cheng,et al.  MiR-221 and miR-222 target PUMA to induce cell survival in glioblastoma , 2010, Molecular Cancer.

[12]  Jia Yu,et al.  miRNA-96 suppresses KRAS and functions as a tumor suppressor gene in pancreatic cancer. , 2010, Cancer research.

[13]  H. Hashimoto,et al.  Identification of altered MicroRNA expression patterns in synovial sarcoma , 2011, Genes, chromosomes & cancer.

[14]  T. Godfrey,et al.  MicroRNA prognostic signature for nodal metastases and survival in esophageal adenocarcinoma. , 2011, The Annals of thoracic surgery.

[15]  M. Babjuk,et al.  Importance of miR-20a expression in prostate cancer tissue. , 2010, Anticancer research.

[16]  Hongwei Zhang,et al.  miRNA-223 Promotes Gastric Cancer Invasion and Metastasis by Targeting Tumor Suppressor EPB41L3 , 2011, Molecular Cancer Research.

[17]  R. Porcher,et al.  Clinical and biological features of t(4;14) multiple myeloma: a prospective study , 2011, Leukemia & lymphoma.

[18]  Michaela Scherr,et al.  Expression of the miR-17-92 polycistron in chronic myeloid leukemia (CML) CD34+ cells. , 2007, Blood.

[19]  Gabriele Sales,et al.  Identification of microRNA expression patterns and definition of a microRNA/mRNA regulatory network in distinct molecular groups of multiple myeloma. , 2009, Blood.

[20]  Á. Zaballos,et al.  Vesicle-related microRNAs in plasma of nonsmall cell lung cancer patients and correlation with survival , 2010, European Respiratory Journal.

[21]  J. M. Thomson,et al.  Transgenic over-expression of the microRNA miR-17-92 cluster promotes proliferation and inhibits differentiation of lung epithelial progenitor cells. , 2007, Developmental biology.

[22]  G. Morgan,et al.  Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma , 2006, Leukemia.

[23]  David J. Galas,et al.  MicroRNA as biomarkers and regulators in B-cell chronic lymphocytic leukemia , 2011, Proceedings of the National Academy of Sciences.

[24]  George A Calin,et al.  MicroRNAs miR-221 and miR-222: a new level of regulation in aggressive breast cancer , 2011, Genome Medicine.

[25]  David R Williams,et al.  High-risk myeloma is associated with global elevation of miRNAs and overexpression of EIF2C2/AGO2 , 2010, Proceedings of the National Academy of Sciences.

[26]  George A. Calin,et al.  MicroRNA identification in plasma and serum: a new tool to diagnose and monitor diseases , 2009, Expert opinion on biological therapy.

[27]  Youliang Wang,et al.  miR-148a Promoted Cell Proliferation by Targeting p27 in Gastric Cancer Cells , 2011, International journal of biological sciences.

[28]  R. Tibshirani,et al.  Significance analysis of microarrays applied to the ionizing radiation response , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[29]  G. Gahrton,et al.  Impact of chromosome 13 deletion and plasma cell load on long-term survival of patients with multiple myeloma undergoing autologous transplantation. , 2009, Oncology reports.

[30]  Ankit Malhotra,et al.  miR-99 family of MicroRNAs suppresses the expression of prostate-specific antigen and prostate cancer cell proliferation. , 2011, Cancer research.

[31]  W. Lam,et al.  Genome-wide identification of human microRNAs located in leukemia-associated genomic alterations. , 2009, Blood.

[32]  Daniel B. Martin,et al.  Circulating microRNAs as stable blood-based markers for cancer detection , 2008, Proceedings of the National Academy of Sciences.

[33]  L. Michaux,et al.  The t(14;20)(q32;q12): a rare cytogenetic change in multiple myeloma associated with poor outcome , 2010, British journal of haematology.

[34]  H. Rehrauer,et al.  Myc-mediated repression of microRNA-34a promotes high-grade transformation of B-cell lymphoma by dysregulation of FoxP1. , 2011, Blood.

[35]  G. Morgan,et al.  Age has a profound effect on the incidence and significance of chromosome abnormalities in myeloma , 2005, Leukemia.

[36]  Thomas D. Schmittgen,et al.  miR-221 silencing blocks hepatocellular carcinoma and promotes survival. , 2011, Cancer research.

[37]  Muller Fabbri,et al.  A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. , 2005, The New England journal of medicine.

[38]  Yingyan Yu,et al.  miRNA-331-3p directly targets E2F1 and induces growth arrest in human gastric cancer. , 2010, Biochemical and biophysical research communications.

[39]  G. Ahmann,et al.  Prognostic factors for hyperdiploid-myeloma: effects of chromosome 13 deletions and IgH translocations , 2006, Leukemia.

[40]  Yuefeng Yang,et al.  Overexpression of microRNA-29b induces apoptosis of multiple myeloma cells through down regulating Mcl-1. , 2011, Biochemical and biophysical research communications.

[41]  Y. Homma,et al.  miR-148a is an androgen-responsive microRNA that promotes LNCaP prostate cell growth by repressing its target CAND1 expression , 2010, Prostate Cancer and Prostatic Diseases.

[42]  R. Gold,et al.  Identification of microRNAs in the cerebrospinal fluid as marker for primary diffuse large B-cell lymphoma of the central nervous system. , 2011, Blood.

[43]  C. Croce,et al.  MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis , 2008, Proceedings of the National Academy of Sciences.